RMD ResMed Inc.

Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study

Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study

  • 2–3 hours of nightly PAP use shows health benefits at 3 months, 1 year, and 2 years

  • Health benefits significantly increase by use hour/night, up to 7 hours

SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Sleep apnea sufferers can gain health benefits from PAP (positive airway pressure) treatment in as little as two hours per night, according to a study led by ResMed (NYSE: RMD, ASX: RMD) and presented at the American Thoracic Society’s annual International Conference.

The retrospective, observational study analyzed the deidentified usage data of 180,000 U.S. PAP users to observe their average rates of all-cause hospitalization and emergency room visits based on the number of nightly hours they use PAP, from zero to nine. Researchers found:1

  • The minimum PAP usage threshold for benefit was 2-3 hours per night (up to 50% lower than the 4 hours required by the U.S. Centers for Medicare and Medicaid and many private payers to prove adherence)
  • Benefits begin at 2 hours of nightly PAP use and increase each hour up to 7 hours per night. Benefits were seen at 90 days, one year, and two years into the study.
  • Over the two years, each additional hour of nightly PAP use reduced:
    • Hospitalizations by 5.0%
    • ER visits by 4.4%

“This study can positively change how healthcare professionals prescribe and encourage sleep apnea sufferers to use PAP – and how they’re covered,” said Atul Malhotra, lead author and research chief of Pulmonary, Critical Care, and Sleep Medicine at the University of California San Diego.

Today, the U.S. Centers for Medicare and Medicaid define PAP therapy adherence as using a PAP device for at least four hours per night for 70% of nights in a consecutive 30-day period in the first 90 days of therapy.2 Patients who do not achieve adherence may risk losing their machine after 90 days or having to pay for it themselves, depending on their insurance coverage.

“If just two hours of nightly PAP use can significantly lower a patient’s risk of getting hospitalized, our health systems should encourage and enable people to access and keep using these solutions,” Malhotra said.

An estimated 54 million Americans have obstructive sleep apnea,3 a chronic disease in which throat muscles relax during sleep, constricting airflow. The body’s resulting jolt “awake” to take a breath causes dozens to hundreds of sleep interruptions per night. Sufferers often aren’t aware of these waking episodes, and 80% remain undiagnosed.4

Read the study’s full abstract .

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

1 Malhotra A et al. Am J Respir Crit Care Med suppl (ATS Abstract) 2022

2 Centers for Medicare & Medicaid Services. /medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=204. Accessed May 2, 2022.

3 Benjafield AV et al. Lancet Resp Med 2019

4 Young T et al. Sleep 1997

For Media

Kristin Deuber

+1 615.975.4186

For Investors

Amy Wakeham

+1 858.836.5000



EN
18/05/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

ResMed Inc: 1 director

A director at ResMed Inc sold 2,000 shares at 260.220USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

Resmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Pr...

Resmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach Insights from 30,000 people across 13 countries show global sleep health awareness is growing, yet an action gap remains  53% of people surveyed rank sleep as the most important behavior for a long, healthy life, ahead of diet and exercise.Over half of respondents get quality sleep on only four nights a week or less.While 66% of people surveyed say they would seek medical help for ongoing sleep issues, just 23% actually do. SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- ...

 PRESS RELEASE

Resmed Expands U.S. Operations with New Distribution Center in Greenwo...

Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana Center to Create Local Jobs and Strengthen U.S. Healthcare Supply Resilience SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distribution center in Greenwood, Indiana. Scheduled to begin operations in 2027, the center will expand Resmed’s U.S. presence and strengthen the company's distribution capacity to better serve patients and providers across North America. The...

 PRESS RELEASE

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 20...

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026 Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP income from operations up 19%Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81Operating cash flow of $340 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today an...

 PRESS RELEASE

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 20...

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:•Location:•Date:Thursday, January 29, 2026•Time:1:30 p.m. PST /...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch